Multiple reports say a new drug for advanced prostate cancer is showing promising results in reducing the likelihood of relapse and slowing the spread of the disease. The coverage states the treatment lowers the risk of the cancer returning by close to one-third compared with existing care, and it also appears to delay progression to more dangerous stages. The articles describe the potential impact as significant for large numbers of men living with advanced prostate cancer, suggesting improved outcomes could follow if the findings lead to broader clinical use. While the reports emphasize the magnitude of the reduction in relapse risk, they do not provide detailed methodology in the supplied text, such as study design, the exact comparator therapy, or the statistical measures used to confirm the results. Overall, the common theme across the sources is that the drug demonstrates both a relapse benefit and an effect on the pace of disease advancement, which the reports present as reasons for cautious optimism for patients facing advanced disease.